CD24, CD27, CD36 and CD302 gene expression could also be combined with a flow cytometry approach using the PrimeFlow® RNA Assay to develop a powerful tool for risk stratification and outcome prediction in MM. The gene discussed is CD24; the disease is Miyoshi myopathy.